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Abstract
The patients with chronic hepatitis C (CHC) are getting older and the demands for treat-
ment to those patients are increasing due to the high risk of development of hepatocel-
lular carcinoma. Elderly patients were previously defined as 60 years and over, however 
definition of the elderly patients shifted to be older year to year. Interferon (IFN) and 
ribavirin combination therapy was significantly improved efficacy of treatment, however 
ribavirin induces anemia, resulted in lower efficacy due to reduction of ribavirin for the 
elderly patients. And efficacy of over 60 years old was comparable to the patients under 
60 years. In the CHC patients with genotype 1, the efficacy of elderly patient was signifi-
cantly lower than that of younger patients, especially in female. Direct-acting antivirals 
(DAAs) therapy makes treatment efficacy improved to over 90% and side effect of treat-
ment was dramatically reduced compared to IFN-based therapy. The efficacy of dual 
oral therapy by using asunaprevir (ASV) and daclatasvir (DCA) for elderly patients with 
hepatitis C virus (HCV) genotype 1b has not been fully clarified. In this article we would 
like to show the efficacy of elderly patients with CHC, especially patients infected with 
genotype 1b, from the era of IFN monotherapy to the era of new DAAs.
Keywords: hepatitis C virus, peginterferon, ribavirin, direct-acting antivirals, elderly 
patient
1. Introduction
The first in the world, the demand for treatment to the elderly patients with chronic hepatitis C 
(CHC) has increased in Japan. The prevalence of anti-hepatitis C virus (HCV) shows the peak 
is in the older generation and the rate of anti-HCV increases with the increase in age in Japan. 
In other country, the peak of prevalence differs from country to country. These differences 
© 2017 The Author(s). Licensee InTech. Distributed under the terms of the Creative Commons Attribut on-
NonCommercial 4.0 License (https://creativecommons.org/l censes/b -nc/4 0/), which permits use, distribution
and reproduction for non-commercial purposes, provided the original is properly cited.
come from one of the reasons when the war was held in each country. During the war, HCV 
infection spread among drug users, blood donors and the wounded. Thereafter medical treat-
ment with intravenous injection using contaminated needles and syringes during that time 
easily transmitted HCV. Therefore in Japan the peak of prevalence of anti-HCV was shifted 
to the older comparing to other country [1]. Previously, we compared SVR rate of ribavirin 
plus interferon (IFN)-α2b in CHC patients aged ≥60 years with patients aged <60 years [2]. 
Our study showed age distribution of the CHC patients treated by IFN-α plus ribavirin was 
peaked around 50 generation in 2002 (Figure 1). At that time we defined over 60 years as 
elderly patients.
2. Ribavirin and IFN-based treatment
The sustained virological response (SVR) rates of treatment in the patients with genotype 1 
and a high viral load aged 60 years and older was below 10% by IFN monotherapy. However, 
SVR rate of IFN and ribavirin combination therapy was significantly improved by over 20%. 
And efficacy of over 60 years old was comparable to the patients under 60 years (Figure 2) [2]. 
In this study adding of ribavirin increased SVR rate, but ribavirin induces anemia, resulted 
in lower SVR rate due to reduction of ribavirin in the elderly patients. During combination of 
IFN-α2b plus ribavirin therapy, over 50 generation and 60 generation had high dose reduc-
tion and cessation of treatment (Figure 3) [2].
Figure 1. Patient age distribution by decade.
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Figure 2. Virologic response to combination therapy and interferon monotherapy. * Indicate significant differences vs the 
respective IFN monotherapy (*P < 0.05). 
Figure 3. Ribavirin dose reduction and discontinuation rates according age of patients.
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3. Ribavirin and PegIFN-based treatment
Peginterferon (PegIFN) plus ribavirin therapy improved the SVR rate of HCV treatment. We 
conducted the study of efficacy of PegIFN-α2b plus ribavirin and the number of the CHC 
patients in that study was 591. The distribution of elderly patients was around 20% in 2007. 
At that time elderly patients were defined as aged 65 years or older [3]. In the CHC patients 
with genotype 1, the SVR rate of elderly patient was significantly lower than that of younger 
patients, especially in female (Figure 4) [3]. On the other hand, patients with genotype 2 had 
comparable SVR rate of elderly patients to the younger patients (Figure 5) [3].
Figure 4. A virological response to combination therapy according to the age and gender of patients with genotype 1.
Figure 5. A virological response to combination therapy according to the age and gender of patients with genotype 2.
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4. DAA-based treatment
Emerge of direct-acting antiviral’s (DAA’s) therapy makes SVR rate improved to over 90% and 
side effect of treatment was dramatically reduced compared to IFN-based therapy. Ribavirin free 
regimen also has benefit for the elderly patients due to avoidance of ribavirin-induced anemia. 
Akuta et al. reported that high SVR rate was achieved by daclatasvir (NS5A replication complex 
inhibitor) (DCA) and asunaprevir (NS3 protease inhibitor) (ASV) even in the elderly patients 
infected with HCV genotype 1b aged 70 and older [4]. They showed predictive factors associ-
ated with SVR12 in elderly patients was NS5A-Y93H mutation under 20%, non-treated by triple 
therapy with simeprevir, lower level of viremia under 6 logIU/mL, hemoglobin under 13.0 g/dl.
We also conducted the study of efficacy of DAA’s therapy for the genotype 1-infected patients 
with CHC. Here we show the results of the patients with DCA and ASV therapy, 287 patients 
were analyzed and the patient’s background shows that patients were getting older and we 
defined elderly patients as aged 70 older. The study protocol was approved by the ethics 
committee of our hospital and affiliated hospital. The inclusion criteria included positive 
anti-HCV and positive HCV RNA and having findings of active hepatitis. Exclusion criteria 
included positive for serum hepatitis B surface antigen, alcohol abuse, autoimmune hepatitis, 
primary biliary cirrhosis, coexisting serious psychiatric or medical illness.
Elderly patients account for 57.8% (166/287) of total treated patients (Table 1). Baseline ALT, 
γ-glutamyl transpeptidase (GGT) hemoglobin and eGFR in elderly patients were significantly 
lower than that of younger patients. Renal function in elderly patients was worse comparing 
Total patients  
(n = 287)
Patients aged  
<70 years (n = 121)
Patients aged  
≥70 years (n = 166)
P value
Sex ratio (male/female) 123/164 55/66 68/98 0.448
Age (years) 72.0 (65.0–77.0) 63.0 (58.0–66.0) 76.0 (73.0–79.0) <0.001
AST (IU/L) 46.0 (35.0–68.0) 48.0 (35.0–75.0) 44.0 (34.0–60.3) 0.124
ALT (IU/L) 39.0 (27.0–63.0) 48.0 (30.5–74.0) 37.0 (23.8–52.3) <0.001
GGT (IU/L) 32.0 (22.0–53.0) 35.0 (22.0–69.0) 29.5 (21.0–46.0) 0.021
Hemoglobin (g/dl) 13.2 (12.0–14.2) 13.5 (12.3–14.4) 13.0 (11.8–14.0) 0.010
Platelets (×104/μL) 12.8 (8.8–17.1) 13.6 (9.2–18.1) 12.4 (8.5–16.8) 0.302
eGFR 71.7 (60.2–84.5) 80.6 (67.8–91.3) 68.2 (56.6–77.0) <0.001




146/5/26/75/25 54/3/14/31/14 92/2/12/44/11 0.276
NS5A Y93H, n (%) 9 (3.1) 6 (5.0) 3 (1.8) 0.122
NS5A L31M, n (%) 4 (1.4) 3 (2.5) 1 (0.6) 0.230
ALT, alanine aminotransferase; GGT, γ-glutamyl transpeptidase; eGFR, estimated glomerular filtration rate; HCV RNA, 
hepatitis C virus RNA; KIU, kilo international units; NVR, null virological response.
Table 1. Baseline clinical characteristics of patients treated with DAA’s therapy.
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to the younger patients as expected. There was no patient with dose reduction due to renal 
insufficiency. The results of DAA’s therapy showed that the SVR24 rate in elderly patients 
was high even in younger patients (92.2 vs. 85.1%). The factors associated with an SVR24 in 
DAA’s therapy were determined by multivariate analysis. Gender [P = 0.014, odds ratio 0.301 
(0.115–0.785)], GGT [P = 0.032, odds ratio 0.992 (0.985–0.999)] and absence of NS5A Y93H 
[P < 0.001, odds ratio 16.50 (3.801–71.66)] were significantly associated with an SVR24 while 
patient age did not affect SVR24. In elderly patients, the factors associated with an SVR24 in 
DAA’s therapy were determined by multivariate analysis. Gender [P = 0.025, odds ratio 
0.071(0.007–0.716)], GGT [P = 0.006, odds ratio 0.982 (0.970–0.995)] and absence of NS5A Y93H 
[P = 0.018, odds ratio 58.47 (2.024–1689.3)] were significantly associated with an SVR24.
5. Prevention of HCC
Aging is one of the factors associated with development of HCC in the CHC patients [5]. IFN 
therapy was reported to have reduction in development of HCC among virological or biochemi-
cal responders [6, 7]. We previously researched how benefit of reduction of HCC after eradi-
cation of HCV by PegIFN plus ribavirin. As shown in the Figure 6 cumulative incidence of 
HCC in the elderly patients was higher than that in the younger patients [8]. However, if the 
elderly patients achieved a SVR, patients have marked reduction of cumulative incidence of 
HCC [8]. From the multivariate analysis in all patients age, advanced fibrosis, treatment efficacy 
and gender was associated with development of HCC. In elderly patients, GGT and treatment 
efficacy were factors associated with development of HCC. Receiver operating characteristic 
Figure 6. Cumulative incidence of HCC after peginterferon alfa-2b and ribavirin in patients who achieved SVR (solid 
line) or did not achieve SVR(dashed line) in younger patients < 65 years old (A) and older patients ≥ 65years old (B).
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(ROC) curve indicated the cut off vale was 44 IU/L to predict for HCC. Among elderly patients 
with GGT < 44 IU/L, the cumulative incidence of HCC in patients with non-SVR was higher 
than patients with SVR, but this difference was not significant (Figure 7A). However, in elderly 
patients with SVR and GGT ≥ 44 IU/L, there was a marked reduction in the development of HCC 
compared with the elderly patients with SVR and GGT ≥ 44 IU/L (elderly patients with GGT < 44 
IU/L, P = 0.265; elderly patients with GGT ≥ 44 IU/L, P = 0.020, log-rank test) (Figure 7B).
6. Discussion
Elderly patients with CHC are getting older and definition of elderly patients shifted from 60 
to 70 years in our study during 13 years. In these days, the change of physical function accord-
ing to age is seen 10 years older than that was seen in 10–20 years ago. Therefore, The Japan 
Geriatrics Society proposed elderly patients are defines as 75 years and over due to these 
rejuvenation phenomenon and the extension of the average life expectancy in 2017. If this 
phenomenon would be seen in all over the world, it will be globally accepted in the future.
DCV/ASV therapy for Japanese elderly patients with CHC had high SVR rate and is compa-
rable to younger patients [4]. Our result indicated there is a possible to be higher SVR rate 
in elderly patients treated by DCV/ASV therapy than that in younger patients. For another 
type of DAA’s therapy Ledipasvir/Sofosbuvir (LDV/SOF) therapy for the older CHC patients 
with genotype 1 from the Phase III had high SVR rate as well as younger patients [9]. They 
Figure 7. Cumulative incidence of HCC after peginterferon alfa-2b and ribavirin in older patients who achieved SVR 
(solid line) or did not achieve SVR(dashed line), among those with GGT < 44 IU/L (A) and GGT ≥ 44 IU/L (B). HCC, 
hepatocellular carcinoma; GGT, gamma-glutamyltranspeptidase; SVR,sustained virological response.
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defined patients aged 65 years or older as elderly patients and those are still small population 
of CHC patients in the United States (12%). In other study CHC patients aged ≥65 years who 
were treated with different combinations of DAAs had high efficacy and took significantly 
more concomitant medications [10]. Therefore, they indicated assessment of concomitant 
medications and drug-drug interactions would be needed before DAAs therapy especially 
for the elderly patients. As well as PegIFN plus ribavirin therapy, DAA’s therapy including 
ribavirin regimen needs close monitoring of anemia in the elderly patients. Elderly patients 
with GGT > 44 IU/L and advanced fibrosis have high risk of development of HCC when we 
treated older CHC patients by PegIFN plus ribavirin. These patients would be high priority 
to be treated with DAA, because patients who achieved SVR had a marked reduction in the 
development of HCC compared with elderly patients who did not achieve SVR. Compared 
to the RBV and IFN or PegIFN-based treatment, DAA-based treatment improved efficacy 
of treatment even in non-elderly patients. Therefore, indication for the elderly patients will 
expand. However, due to the high costs of current DAA’s therapy at the moment, it is better 
to evaluate life expectancy. Higher age, HCV-related liver disease (advanced fibrosis, HCC) 
and other concomitant disease affect life expectancy. Elderly patients took many other medi-
cations, therefore evaluation of drug-drug interaction between DAA and other medication is 
necessary. If HCV-related liver diseases are likely to affect survival and quality of life (QOL) 
and there are no economic restrictions in country where patients will be treated, the patients 
are better to be treated. If HCV-related liver diseases are not likely to affect survival and QOL 
or there are economic restrictions in that country, the patients should be closely monitored 
and be regularly reevaluated. Therefore, physician needs more knowledge of interaction of 
other diseases and to have a long-term of view on the CHC patients.
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